Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefan Duensing

Showing results (61-70 of 139) with videos related to

Pageof 14
Sort By:
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology|April 2, 2020
Microenvironment-Derived FGF-2 Stimulates Renal Cell Carcinoma Cell Proliferation through Modulation of p27Kip1: Implications for Spatial Niche Formation and Functional Intratumoral HeterogeneityWeibin Hou, Adam Kaczorowski, Philippa Lantwin, et al.
The American Journal of Pathology|March 26, 2016
IL-6 Overexpression in ERG-Positive Prostate Cancer Is Mediated by Prostaglandin Receptor EP2Constanze Merz, Anne von Mässenhausen, Angela Queisser, et al.
Cancer Treatment and Research Communications|July 4, 2020
Antibody selection influences the detection of AR-V7 in primary prostate cancerAdam Kaczorowski, Xin Chen, Esther Herpel, et al.
Future Science OA|May 26, 2018
Prospective single center trial of next-generation sequencing analysis in metastatic renal cell cancer: the MORE-TRIALSvenja Dieffenbacher, Stefanie Zschäbitz, Luisa Hofer, et al.
Clinical Genitourinary Cancer|January 19, 2015
Efficacy of targeted treatment beyond third-line therapy in metastatic kidney cancer: retrospective analysis from a large-volume cancer centerSonia Vallet, Sascha Pahernik, Thomas Höfner, et al.
Cancer Research|March 17, 2007
Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylateYing Liu, Michelle Tseng, Sophie A Perdreau, et al.
Urologia Internationalis|April 27, 2022
Interleukin-2 and Interferon-α for Advanced Renal Cell Carcinoma: Patient Outcomes, Sexual Dimorphism of Responses, and Multimodal Treatment Approaches over a 30-Year PeriodEva Bonetti, Maximilian Jenzer, Cathleen Nientiedt, et al.
Digital Health|May 8, 2023
An artificial intelligence-based chatbot for prostate cancer education: Design and patient evaluation studyMagdalena Görtz, Kilian Baumgärtner, Tamara Schmid, et al.
Cancers|December 23, 2023
Long-Term Survival of Patients with Stage T1N0M1 Renal Cell CarcinomaViktoria Schütz, Huan Lin, Adam Kaczorowski, et al.
NPJ Precision Oncology|March 2, 2026
Multimodal plasma and urinary cell-free DNA profiling improves risk stratification in newly diagnosed prostate cancerAnja Lisa Riediger, Samaneh Eickelschulte, Florian Janke, et al.
Pageof 14

Showing results (61-70 of 139) with videos related to

Sort By:
Pageof 14
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology|April 2, 2020
Microenvironment-Derived FGF-2 Stimulates Renal Cell Carcinoma Cell Proliferation through Modulation of p27Kip1: Implications for Spatial Niche Formation and Functional Intratumoral HeterogeneityWeibin Hou, Adam Kaczorowski, Philippa Lantwin, et al.
The American Journal of Pathology|March 26, 2016
IL-6 Overexpression in ERG-Positive Prostate Cancer Is Mediated by Prostaglandin Receptor EP2Constanze Merz, Anne von Mässenhausen, Angela Queisser, et al.
Cancer Treatment and Research Communications|July 4, 2020
Antibody selection influences the detection of AR-V7 in primary prostate cancerAdam Kaczorowski, Xin Chen, Esther Herpel, et al.
Future Science OA|May 26, 2018
Prospective single center trial of next-generation sequencing analysis in metastatic renal cell cancer: the MORE-TRIALSvenja Dieffenbacher, Stefanie Zschäbitz, Luisa Hofer, et al.
Clinical Genitourinary Cancer|January 19, 2015
Efficacy of targeted treatment beyond third-line therapy in metastatic kidney cancer: retrospective analysis from a large-volume cancer centerSonia Vallet, Sascha Pahernik, Thomas Höfner, et al.
Cancer Research|March 17, 2007
Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylateYing Liu, Michelle Tseng, Sophie A Perdreau, et al.
Urologia Internationalis|April 27, 2022
Interleukin-2 and Interferon-α for Advanced Renal Cell Carcinoma: Patient Outcomes, Sexual Dimorphism of Responses, and Multimodal Treatment Approaches over a 30-Year PeriodEva Bonetti, Maximilian Jenzer, Cathleen Nientiedt, et al.
Digital Health|May 8, 2023
An artificial intelligence-based chatbot for prostate cancer education: Design and patient evaluation studyMagdalena Görtz, Kilian Baumgärtner, Tamara Schmid, et al.
Cancers|December 23, 2023
Long-Term Survival of Patients with Stage T1N0M1 Renal Cell CarcinomaViktoria Schütz, Huan Lin, Adam Kaczorowski, et al.
NPJ Precision Oncology|March 2, 2026
Multimodal plasma and urinary cell-free DNA profiling improves risk stratification in newly diagnosed prostate cancerAnja Lisa Riediger, Samaneh Eickelschulte, Florian Janke, et al.
Pageof 14